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The DNA sequencing techniques became available 
in 1970s. The technique developed by Sanger and 
colleague, referred to as Sanger Sequencing, 
became the most widely used method in DNA 
sequencing projects including the most famous 
Human Genome Project (HGP).1 The first draft 
human genome sequence was published separately 
by a public sector group, International Human 
Genome Sequencing Consortium (IHGSC), in Nature 
and by a private sector group, Celera Genomics, in 
Science in 2001.1 The estimated cost for HGP was 3 
billion USD over a span of 15 years but this cost and 
time reduced to 300 million in 2 years due to the 
rapid technical advancements.2 In 2004, The 
National Human Genome Research Institute 
(NHGRI) started a funding program aimed to reduce 
the sequencing cost to 1000 USD which paved the 
path for development of the Next Generation 
Sequencing (NGS) technologies, also known as high  
throughput sequencing technologies.1  
The first NGS technology was introduced by 454 
Life Sciences (now Roche) in 2004 which utilized 
pyrosequencing method. Illumina sequencing 
platform and Sequencing by Oligo Ligation 
Detection (SOLiD) by Applied Biosystems (now Life 
Technologies) were commercialized in 2006 and 
2007, respectively.3 Other NGS methods are also  
 
 
available like Ion torrent, Pacific Bioscience and 
Oxford Nanopore but so far, Illumina holds the 
major market share due to availability of wide 
range of cost effective platforms.2 The Illumina’s 
recently introduced NovaSeq 6000 system 
(www.illumina.com) has the capability of 
generation of 6 Terabyte data per run with fastest 
run time of 1-2 days with much reduced price but 
their promise of reducing sequencing cost per 
genome to 100 USD is still to be fulfilled. 
The rapid drop in sequencing prices paved the path 
for clinical implementation of NGS technology. NGS 
has been used in cancer genomics, personalized 
medicine, forensic science, HLA typing and organ 
transplantation, clinical microbiology, prenatal 
diagnostics, new born screening and in 
identification of genetic players in rare disorders 
(Figure 1). Rare disorders, although individually 
uncommon but collectively affect millions of people 
worldwide. These disorders occur due to mutations 
in single gene affecting its function and so far, 7000 
rare disorders are known to occur with almost 
15000 genes being involved.4 For molecular 
diagnosis of rare disorders, NGS based targeted 
gene panels are most commonly used for 
identification of mutation in genes already known 
to cause a disease.5 Whole exome sequencing 
(WES), which targets only protein coding portion of  
the genome (~1%), is the second best option for 
identification of pathogenic mutations in already 
known and novel genes4 Identification of disease 
gene will help to unravel the molecular pathways 
which will be helpful in exploring therapeutic 
options. Currently, direct therapeutic approaches 
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such as DNA replacement by gene therapy, protein 
/enzyme replacement therapy, transcriptional 
downregulation by antisense oligonucleotides or 
RNA interference and disease gene correction by 
using genome editing techniques are in clinical or 
pre-clinical trials. Beside these, rapid low cost and 
low risk therapies for rare diseases is also practiced 
such as dietary substrate omission or 
supplementation as in case of phenylketonuria, 
maple syrup urine disease and some other 
metabolic disorders.4 
Figure 1: Clinical Applications of Next Generation 
Sequences 
In Pakistan, 17-38% marriages are consanguineous 
which have been long known to increase the risk of  
congenital disorders among children.6 Large scale 
genetic studies have been conducted on Pakistani 
families affected with various rare disorders by 
using next generation sequencing technologies 
which has led to identification of several novel 
genes and novel mutations in already known genes. 
Genetic analysis of 23 family affected with 
autosomal recessive primary microcephaly revealed 
that most of the disease-causing mutations were 
harbored by ASPM and WDR62.7 A study conducted 
on 60 families affected with Intellectual disability 
(ID) by using whole exome sequencing helped in 
identification of 30 novel candidate disease causing 
genes.8  
In another study, 192 ID affected consanguineous 
families, belonging to Pakistan and Iran were 
studied which helped in identification of 26 new ID 
causing genes.9 Targeted NGS on 12 Pakistani 
families affected with syndromic or non-syndromic 
hearing loss helped in identification of 8 novel 
disease causing variants in known genes.10 In 
another study, whole exome sequencing helped in 
developing molecular diagnosis for almost half of 
the cases in familial cohort inheriting retinal 
degeneration.11 Thus implementation of NGS 
technology in clinical practice for rare disease 
diagnosis by designing population specific gene 
panels or by whole exome sequencing are the two 
cost effective approaches which will not only 
shorten the time for disease diagnosis but will also 
help in deciding therapeutic options available to 
the patient. 
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